Trade Name Stemgen
Orphan Indication For use in combination with filgrastim to decrease the number of phereses required to collect peripheral blood progenitor cells capable of providing rapid multi-lineage hematopoietic reconstitution following myelosuppressive or myeloablative therapy
USA Market Approval USA
USA Designation Date 1995-07-05 00:00:00
Sponsor Amgen, Inc.;One Amgen Center Drive;Thousand Oaks, California, 91320